Asset
IOPOFOSINE I-131
CELLECTAR BIOSCIENCES INC. COMMON STOCK
Revenue
No revenue reported in loaded filings.
Clinical trials (7)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT03478462 | phase1 | active_not_recruiting | 2019-04-30 | 2027-06-30 | Cellectar Biosciences, Inc. | Dose Escalation Study of CLR 131 in Pediatric Relapsed/Refractory Malignant Tumors Including Neuroblastoma and Sarcomas |
| NCT02278315 | phase1 | completed | 2015-02-01 | 2020-12-09 | Cellectar Biosciences, Inc. | Dose Escalation Study of I-131-CLR1404 in Patients With Relapsed or Refractory Multiple Myeloma |
| NCT01495663 | phase1 | completed | 2011-12-01 | 2013-11-01 | Cellectar Biosciences, Inc. | Dose Escalation Study of I-131-CLR1404 in Subjects With Cancer That Does Not Respond to Treatment or Has Returned |
| NCT00925275 | phase1 | completed | 2009-06-01 | 2010-02-01 | Cellectar, Inc | Dosimetry Study of I-131-CLR1404 in Patients With Relapsed or Refractory Advanced Solid Tumors |
| NCT07766421 | phase3 | not_yet_recruiting | 2026-12-01 | 2032-01-01 | Cellectar Biosciences, Inc. | Evaluation of Iopofosine I 131 vs. R-CD in WM Patients |
FDA applications (0)
This company has no applications containing this asset.